Orexo Overview
- Year Founded
-
1995

- Status
-
Public
- Employees
-
113

- Stock Symbol
-
ORX

- Investments
-
3
- Share Price
-
$1.54
- (As of Tuesday Closing)
Orexo General Information
Description
Orexo AB has operations in Sweden and the United States. Operations are monitored and presented in the segments USA Pharma, Digital Therapeutics (DTx), and HQ & Pipeline. The majority is from the USA Pharma segment. Geographically, the majority is derived from the United States. USA Pharma includes the commercialization of fully owned pharmaceuticals in the United States market. Digital Therapeutics include the commercialization of Orexo's groundbreaking evidence-based digital therapeutics, mainly in the United States market, which is in an early development stage. HQ &Pipeline includes the Development of pharmaceuticals performed at Orexo's headquarters in Uppsala, Sweden.
Contact Information
Website
www.orexo.comCorporate Office
- Virdings Allé 32 A
- 754 50 Uppsala
- Sweden
Corporate Office
- Virdings Allé 32 A
- 754 50 Uppsala
- Sweden
Orexo Stock Performance
As of 11-Feb-2025, Orexo’s stock price is $1.54. Its current market cap is $53M with 34.5M shares.
(As of Tuesday Closing)
Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
---|---|---|---|---|---|---|
$1.54 | $1.62 | $0.83 - $2.24 | $53M | 34.5M | 42K | -$0.56 |
Orexo Financials Summary
As of 31-Dec-2024, Orexo has a trailing 12-month revenue of $55.8M.
In Thousands, USD |
TTM 31-Dec-2024 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
---|---|---|---|---|
EV | 102,206 | 102,206 | 80,179 | 70,734 |
Revenue | 55,787 | 55,787 | 60,099 | 61,539 |
EBITDA | 4,624 | 4,624 | (3,058) | (7,679) |
Net Income | (19,195) | (19,195) | (12,071) | (17,506) |
Total Assets | 53,909 | 53,909 | 78,708 | 106,310 |
Total Debt | 43,141 | 43,141 | 47,409 | 51,726 |
Orexo Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
Orexo Comparisons
Industry
Financing
Details
Orexo Competitors (12)
One of Orexo’s 12 competitors is AstraZeneca, a Formerly PE-Backed company based in Cambridge, United Kingdom.
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
AstraZeneca | Formerly PE-Backed | Cambridge, United Kingdom | ||||
Sun Pharmaceutical Industries | Corporation | Mumbai, India | ||||
Novartis India | Corporation | Mumbai, India | ||||
Targanta Therapeutics Corporation | Corporation | Parsippany, NJ | ||||
Novartis | Corporation | Basel, Switzerland |
Orexo Patents
Orexo Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
GB-202319899-D0 | New composition | Pending | 22-Dec-2023 | ||
GB-202315885-D0 | New composition | Pending | 17-Oct-2023 | ||
GB-202308121-D0 | New composition | Pending | 31-May-2023 | ||
GB-202308123-D0 | New copmosition | Pending | 31-May-2023 | ||
GB-202213306-D0 | New pharmaceutical composition | Inactive | 12-Sep-2022 |
Orexo Signals
Orexo Acquisitions (3)
Orexo’s most recent deal was a Merger/Acquisition with PharmaKodex for . The deal was made on 21-Aug-2009.
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
PharmaKodex | 21-Aug-2009 | Merger/Acquisition | Pharmaceuticals | ||
Biolipox | 23-Nov-2007 | Merger/Acquisition | Drug Discovery | ||
CePep | 29-Aug-2003 | Merger/Acquisition | Biotechnology |
Orexo ESG
Risk Overview
Risk Rating
Updated May, 31, 2024
38.92 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 15,120
Rank
Percentile

Pharmaceuticals
Industry
of 853
Rank
Percentile

Pharmaceuticals
Subindustry
of 425
Rank
Percentile

Affiliates
Subsidiaries (1)
Name | Industry | Location | Year Founded |
---|---|---|---|
Biolipox | Solna, Sweden | 2000 |
Orexo FAQs
-
When was Orexo founded?
Orexo was founded in 1995.
-
Where is Orexo headquartered?
Orexo is headquartered in Uppsala, Sweden.
-
What is the size of Orexo?
Orexo has 113 total employees.
-
What industry is Orexo in?
Orexo’s primary industry is Pharmaceuticals.
-
Is Orexo a private or public company?
Orexo is a Public company.
-
What is Orexo’s stock symbol?
The ticker symbol for Orexo is ORX.
-
What is the current stock price of Orexo?
As of 11-Feb-2025 the stock price of Orexo is $1.54.
-
What is the current market cap of Orexo?
The current market capitalization of Orexo is $53M.
-
What is Orexo’s current revenue?
The trailing twelve month revenue for Orexo is $55.8M.
-
Who are Orexo’s competitors?
AstraZeneca, Sun Pharmaceutical Industries, Novartis India, Targanta Therapeutics Corporation, and Novartis are some of the 12 competitors of Orexo.
-
What is Orexo’s annual earnings per share (EPS)?
Orexo’s EPS for 12 months was -$0.56.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »